Original Article
Discrepancies in Cardiovascular Disease Risk Calculation Affect Aspirin Use Recommendations in Patients with Diabetes
Abstract
Objectives: Aspirin is recommended for cardiovascular disease (CVD) prevention in patients who are at high risk for CVD. The objective of this study was to compare agreement between two American Diabetes Association–endorsed CVD risk calculators in identifying candidates for aspirin therapy.Methods: Adult patients with diabetes mellitus (n = 238) were studied for 1 year in a family medicine clinic. Risk scores were calculated based on the United Kingdom Prospective Diabetes Study Risk Engine and the Atherosclerosis Risk in Communities Coronary Heart Disease Risk Calculator. Analyses included χ 2 , κ scores, and logistic regressions.
Results: The Atherosclerosis Risk in Communities Coronary Heart Disease Risk Calculator identified 50.4% of patients as high risk versus 23.5% by the United Kingdom Prospective Diabetes Study Risk Engine. κ score for agreement identifying high-risk status was 0.3642. Among patients at high risk, African Americans (odds ratio [OR] 0.45, 95% confidence interval [CI] 0.24–0.86) and those with uncontrolled diabetes (OR 0.30, 95% CI 0.16–0.56) had lower odds of disagreement, whereas nonsmokers had higher odds (OR 2.98, 95% CI 1.57–5.69). Among patients at low risk, women (OR 3.83, 95% CI 1.64–8.91), African Americans (OR 5.96, 95% CI 3.07–11.59), and those with high high-density lipoprotein (OR 2.82, 95% CI 1.48–5.37) showed greater odds of disagreement.
Conclusions: Improved risk assessment methods are needed to identify patients with diabetes mellitus who benefit from aspirin for the primary prevention of CVD. Prospective trials are needed to provide additional evidence for aspirin use in this population.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Wilson PW. Diabetes mellitus and coronary heart disease. Am J Kidney Dis 1998;32:S89-S100.
2. McGill HC Jr, McMahan CA. Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Cardiol 1998;82:30T-36T.
3. Gorina Y, Lentzner H. Trends in health and aging: multiple causes of death in old age. http://www.cdc.gov/nchs/data/ahcd/agingtrends/09causes.pdf. Published February 2008. Accessed July 30, 2012.
4. Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989;14:49-57.
5. Singer DE, Moulton AW, Nathan DM. Diabetic myocardial infarction. Interaction of diabetes with other preinfarction risk factors. Diabetes 1989;38:350-357.
6. Smith JW, Marcus FI, Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol 1984;54:718-721.
7. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-126.
8. Tehrani A, Antovic A, Mobarrez F, et al. High-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetes. Diabetes Care 2012;35:404-408.
9. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007;109:2285-2292.
10. Cubbon RM, Gale CP, Rajwany A, et al. Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. Diabetes Care 2008;31:363-365.
11. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
12. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-2141.
13. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840.
14. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150:405-410.
15. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:396-404.
16. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010;121:2694-2701.
17. American Diabetes Association. Standards of Medical Care in Diabetes 2012. Diabetes Care 2012;35:S11-S63.
18. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes. (UKPDS 56) Clin Sci (Lond) 2001;101:671-679.
19. Chambless LE, Folsom AR, Sharrett AR, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol 2003;56:880-890.
20. American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011;34:S11-S61.
21. Allan GM, Nouri F, Korownyk C, et al. Agreement among cardiovascular disease risk calculators. Circulation 2013;127:1948-1956.
22. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013;November 12 [Epub ahead of print] .
23. Centers for Disease Control and Prevention. Prevalence of coronary heart disease--United States, 2006-2010. MMWR Morb Mortal Wkly Rep 2011;60;1377-1381.
24. Fang J, Shaw KM, George MG. Prevalence of stroke--United States, 2006-2010. MMWR Morb Mortal Wkly Rep 2012;61;379-382.
25. Ford ES. Trends in the risk for CHD among adults with diagnosed diabetes in the US. Diabetes Care 2011;34:1337-1343.
26. Folsom AR, Szklo MStevens J, et al. A prospective study of CHD in relation to fasting insulin, glucose and diabetes: the ARIC study. Diabetes Care 1997;20:935-942.
27. Kothari V, Stevens RJ, Adler AI, et al. Risk of stroke in type 2 diabetes estimated by the UKPDS risk engine. Stroke 2002;33:1776-1781.
28. Folsom AR, Chambless LE, Duncan BB, et al. Prediction of Coronary Heart Disease in Middle-Aged Adults With Diabetes. Diabetes Care 2003;26:2777-2784.
29. British Heart Foundation and University of Oxford. A Study of Cardiovascular Events in Diabetes (ASCEND). http://www.ctsu.ox.ac.uk/ascend/about_pro.htm. Accessed July 30, 2012.
30. Aspirin and simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D). http://controlled-trials.com/isrctn/pf/48110081. Published November 2, 2009. Accessed July 30, 2012.
